Comprehensive medication guide to {drug} including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Hadlima (adalimumab-bwwd) is a biosimilar to Humira, manufactured by Organon. It is a TNF (tumor necrosis factor) blocker used to treat a range of autoimmune and inflammatory conditions. Hadlima is FDA-approved for moderately to severely active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease (adults and pediatric patients 6+), ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, juvenile idiopathic arthritis (ages 2+), and non-infectious uveitis in adults.
As a biosimilar, Hadlima has been shown to be highly similar to Humira with no clinically meaningful differences in safety, purity, or potency. It offers a more affordable alternative to the reference product.
Hadlima is a fully human monoclonal antibody that targets and binds to tumor necrosis factor-alpha (TNF-α), a key protein involved in inflammation. In autoimmune conditions, the body produces excess TNF-α, which drives chronic inflammation and tissue damage. By binding to TNF-α, Hadlima blocks it from interacting with cell surface TNF receptors, effectively reducing the inflammatory response.
Hadlima is administered by subcutaneous injection, typically 40 mg every other week. Some conditions require an initial loading dose of 80–160 mg. Patients can self-inject at home after receiving proper training from their healthcare provider. Injection sites include the thigh or abdomen, and sites should be rotated with each dose.
The citrate-free formulations (0.4 mL) may cause less injection site pain compared to the original 0.8 mL formulations.
Hadlima scores a 40 out of 100 on our findability scale, meaning it can be moderately difficult to locate in stock. As a newer adalimumab biosimilar (launched July 2023), many pharmacies have been slow to stock it. Availability issues stem from formulary transitions, limited pharmacy adoption of biosimilars, and the fact that many pharmacists still default to dispensing Humira. While Hadlima is not listed on the FDA drug shortage database, patients frequently report difficulty finding it at their local pharmacy. Specialty pharmacies and mail-order services tend to have better availability. Using Medfinder can help you quickly locate pharmacies near you that have Hadlima in stock.
Struggling to find {drug} in stock? We'll call the pharmacies, sit on hold, and find you one that can fill your prescription.
Hadlima is most commonly prescribed by specialists, including:
Because Hadlima is a biologic with serious potential side effects, most patients are referred to a specialist before starting treatment. Prior authorization from insurance is typically required.
No, Hadlima is not a controlled substance. It is not classified under any DEA schedule. However, it does carry a boxed warning regarding increased risk of serious infections (including tuberculosis and invasive fungal infections) and malignancies (including lymphoma). Patients must be screened for latent tuberculosis before starting Hadlima, and ongoing monitoring is required during treatment.
Serious side effects (seek medical attention immediately):
Hadlima carries a boxed warning about serious infections and malignancies. Your doctor will monitor you closely during treatment.
Several alternatives exist, including other adalimumab biosimilars and different biologic agents:
Talk to your doctor about which option is best suited for your condition and insurance coverage.
Hadlima can interact with several medications. Key interactions include:
Always inform your healthcare provider of all medications and supplements you are taking before starting Hadlima.
Hadlima is a valuable biosimilar option for patients who need adalimumab therapy but want a more affordable alternative to Humira. With a wholesale acquisition cost of approximately $1,038 per carton compared to Humira's $6,922, the savings can be substantial. Organon also offers a $0 co-pay savings card for eligible commercially insured patients, and patient assistance programs are available for the uninsured or underinsured.
The biggest challenge with Hadlima is finding it in stock. As a relatively new biosimilar, pharmacy adoption is still ramping up, and not all pharmacies routinely carry it. If your local pharmacy doesn't have Hadlima, consider asking them to order it, checking specialty pharmacies, or using Medfinder to locate nearby pharmacies with availability.
%2C%20Color%3DOriginal.png)
